The University of Chicago has long recognized the importance of physician scientists capable of utilizing laboratory discoveries to evolve novel therapeutic approaches and using clinical observations to inform and shape basic investigations. The University has an enviable record of training the next generation of academic oncologists. However, the training of academic leaders with critical expertise in clinical and translational research has become increasingly difficult, mandating the creation of a tightly structured and mentored training environment. Leveraging our current training programs (CTSA, K30 award, non-Roadmap K12 awards, traditional T32 training, K08/K23 mentoring programs), we will create an interdisciplinary program in patient-oriented research to train clinicians and basic scientists to lead interdisciplinary teams that will transform the practice of oncology. The Paul Calabresi K12 Scholars Program is our highly mentored, didactic coursework-intensive program, and """"""""hands on"""""""" clinical research training which results in a Master of Science in Health Studies. These scholars are clinical oncologists finishing fellowship training, clinical faculty who wish to change career emphasis, or a scientist with a health-related PhD who wishes to work in the clinical sphere. The strength of our clinical programs coupled with our research intensity and our focus on genetics/genomics research makes the University of Chicago an ideal institution for the preparation of a clinical oncology workforce for the era of personalized medicine. Through this training program will emerge bonafide translational researchers and clinical oncologists who will possess the knowledge and capacity to conduct bench to bedside research and translate their findings back to patients and the population. It is our expectation that individuals completing this program will have obtained the broad research training and comprehensive experience necessary to perform high quality and high impact hypothesis-based clinical and translational research and to make fundamental contributions towards the goal of personalized cancer treatment. An explicit goal of this Paul Calabresi Scholars program, as with all training programs in our institution, is that its training opportunities and benefits will extend far beyond the relatively few scholars whose stipends it will provide. We are confident that the program will reach into the larger oncology trainee community at our University and in Chicago and to young scientists pursuing careers in cancer research all over the globe. Thus, the benefit that accrues from the program's implementation will be substantial.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Physician Scientist Award (Program) (PSA) (K12)
Project #
5K12CA139160-04
Application #
8540128
Study Section
Subcommittee G - Education (NCI)
Program Officer
Damico, Mark W
Project Start
2010-08-12
Project End
2015-07-31
Budget Start
2013-08-01
Budget End
2014-07-31
Support Year
4
Fiscal Year
2013
Total Cost
$726,213
Indirect Cost
$61,836
Name
University of Chicago
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
005421136
City
Chicago
State
IL
Country
United States
Zip Code
60637
Samaeekia, Ravand; Adorno-Cruz, Valery; Bockhorn, Jessica et al. (2017) miR-206 Inhibits Stemness and Metastasis of Breast Cancer by Targeting MKL1/IL11 Pathway. Clin Cancer Res 23:1091-1103
Sweis, Randy F; Luke, Jason J (2017) Mechanistic and pharmacologic insights on immune checkpoint inhibitors. Pharmacol Res 120:1-9
Applebaum, Mark A; Desai, Ami V; Glade Bender, Julia L et al. (2017) Emerging and investigational therapies for neuroblastoma. Expert Opin Orphan Drugs 5:355-368
Wang, Daniel Y; Eroglu, Zeynep; Ozgun, Alpaslan et al. (2017) Clinical Features of Acquired Resistance to Anti-PD-1 Therapy in Advanced Melanoma. Cancer Immunol Res 5:357-362
Saloura, Vassiliki; Vougiouklakis, Theodore; Zewde, Makda et al. (2017) WHSC1L1-mediated EGFR mono-methylation enhances the cytoplasmic and nuclear oncogenic activity of EGFR in head and neck cancer. Sci Rep 7:40664
Wood, Kevin; Byron, Elizabeth; Janisch, Linda et al. (2017) Capecitabine and Celecoxib as a Promising Therapy for Thymic Neoplasms. Am J Clin Oncol :
Mehrotra, Shailly; Sharma, Manish R; Gray, Elizabeth et al. (2017) Kinetic-Pharmacodynamic Model of Chemotherapy-Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel, or Ixabepilone: CALGB 40502 (Alliance). AAPS J 19:1411-1423
Applebaum, Mark A; Vaksman, Zalman; Lee, Sang Mee et al. (2017) Neuroblastoma survivors are at increased risk for second malignancies: A report from the International Neuroblastoma Risk Group Project. Eur J Cancer 72:177-185
Fuchsberger, Christian (see original citation for additional authors) (2016) The genetic architecture of type 2 diabetes. Nature 536:41-47
Shoushtari, Alexander N; Munhoz, Rodrigo R; Kuk, Deborah et al. (2016) The efficacy of anti-PD-1 agents in acral and mucosal melanoma. Cancer 122:3354-3362

Showing the most recent 10 out of 92 publications